期刊
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
卷 23, 期 8, 页码 1227-1241出版社
SPRINGER
DOI: 10.1007/s00775-018-1606-0
关键词
Aroylhydrazones; MPAC; Alzheimer's disease; Zinc(II); A beta peptide
资金
- FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Brazil)
- CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil)
- CNPq
- CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil)
With the increasing life expectancy of the world's population, neurodegenerative diseases, such as Alzheimer's disease (AD), will become a much more relevant public health issue. This fact, coupled with the lack of efficacy of the available treatments, has been driving research directed to the development of new drugs for this pathology. Metal-protein attenuating compounds (MPACs) constitute a promising class of agents with potential application on the treatment of neurodegenerative diseases, such as AD. Currently, most MPACs are based on 8-hydroxyquinoline. Recently, our research group has described the hybrid aroylhydrazone containing the 8-hydroxyquinoline group INHHQ as a promising MPAC. By studying the known structure-related ligand HPCIH, which does not contain the phenol moiety, as a simplified chemical model for INHHQ, we aimed to clarify the real impact of the aroylhydrazone group for the MPAC activity of a compound with potential anti-Alzheimer's activity. The present work describes a detailed solution and solid-state study of the coordination of HPCIH with Zn2+ ions, as well as its in vitro binding-ability towards this metal in the presence of the A beta(1-40) peptide. Similar to INHHQ, HPCIH is able to efficiently compete with A beta(1-40) for Zn2+ ions, performing as expected for an MPAC. The similarity between the behaviors of both ligands is remarkable. Taken together, the data presented herein point to aroylhydrazones, such as the compounds HPCIH and the previously published INHHQ, as encouraging MPACs for the treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据